MGTX vs NGNE
MGTX: A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology. NGNE: Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating neurological diseases.
Side-by-side fundamentals
| Metric | MGTX | NGNE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $12.16 | $36.11 | |
| Market cap as of 2026-07-23 | $1.1B | $721M | |
| PEG as of 2026-07-23 | n/a | -1.00 | |
| Net margin as of 2026-07-23 | -151.1% | -8123.7% | MGTX higher |
| Gross margin as of 2026-07-23 | +95.4% | n/a | |
| Operating margin as of 2026-07-23 | -131.9% | -8930.3% | MGTX higher |
| ROE as of 2026-07-23 | -315.6% | -25.3% | NGNE higher |
| ROA as of 2026-07-23 | -55.0% | -23.3% | NGNE higher |
| Debt / equity as of 2026-07-23 | 24.92 | 0.00 | NGNE lower |
| Revenue growth (YoY) as of 2026-07-23 | +131.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +141.0% | n/a | |
| Beta as of 2026-07-23 | 1.25 | 1.67 | |
| 1-year return as of 2026-07-22 close | +41.6% | +64.6% | NGNE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.